Halozyme shines with strong growth and partnerships, while Synopsys struggles after earnings miss and lowered outlook.
When it was '21, it was a very weird year - and it seems the same can be said for '22, maybe more so. Yet here we all are, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback